

**Brain Tumour Organization of Canada**  
**Financial Statements**  
*December 31, 2022*

	<i><b>Page</b></i>
<b>Independent Auditor's Report</b>	
<b>Financial Statements</b>	
Statement of Operations and Changes in Net Assets.....	1
Statement of Financial Position.....	2
Statement of Cash Flows.....	3
<b>Notes to the Financial Statements.....</b>	<b>4 - 12</b>

To the Board of Directors of Brain Tumour Organization of Canada:

## Report on the Audit of the Financial Statements

### Qualified Opinion

We have audited the accompanying financial statements of Brain Tumour Organization of Canada (the "Organization"), which comprise the statement of financial position as at December 31, 2022, the statement of operations and changes in net assets, and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of Brain Tumour Organization of Canada as at December 31, 2022 and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

### Basis for Qualified Opinion

In common with many not-for-profit organizations, the Organization derives revenue from fundraising events and donations, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, our verification of these revenues was limited to the amounts recorded in the records of the Organization. Therefore, we were not able to determine whether any adjustments might be necessary to fundraising events revenues, donations revenues, excess of revenues over expenditures and its cash flows for the years ended December 31, 2022 and December 31, 2021, current assets and fund balances as at December 31, 2022 and December 31, 2021.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Organization in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.

### Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Organization's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Organization or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Organization's financial reporting process.

### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Organization's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Organization to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### **Report on Other Legal and Regulatory Requirements**

As required by the Corporations Act of Ontario, we report that, in our opinion, the accounting principles in Canadian accounting standards for not-for-profit organizations have been applied on a basis consistent with that of the preceding year.

*MNP LLP*

London, Ontario

March 29, 2023

Chartered Professional Accountants

Licensed Public Accountants

**Brain Tumour Foundation of Canada**  
**Statement of Operations and Changes in Net Assets**  
**Year ended December 31, 2022**

	Unrestricted Fund	Restricted Fund	Endowment Fund	Total 2022	Total 2021
<b>Revenues</b>					
Fundraising events	\$ 1,550,420	\$ 330,298	\$ -	\$ 1,880,718	\$ 2,209,844
Donations	984,937	291,283	1,429	1,277,649	1,245,190
Other revenue (note 12)	14,620	240	-	14,860	3,676
Investment income (note 13)	(204,419)	-	(23,815)	(228,234)	193,626
	<b>2,345,558</b>	<b>621,821</b>	<b>(22,386)</b>	<b>2,944,993</b>	<b>3,652,336</b>
<b>Fundraising expenditures</b>					
Fundraising events	77,716	-	-	77,716	50,272
Other fundraising	383,161	-	-	383,161	368,145
	<b>460,877</b>	<b>-</b>	<b>-</b>	<b>460,877</b>	<b>418,417</b>
<b>Program expenditures</b>					
Patient services	1,679,178	18,101	-	1,697,279	1,576,014
Research	11,000	719,461	-	730,461	524,886
	<b>1,690,178</b>	<b>737,562</b>	<b>-</b>	<b>2,427,740</b>	<b>2,100,900</b>
<b>Administration expenditures</b>					
Salaries	104,598	-	-	104,598	98,185
Office and general	119,163	-	3,643	122,806	134,111
Amortization	3,550	-	-	3,550	3,822
Miscellaneous	5,667	-	-	5,667	5,496
	<b>232,978</b>	<b>-</b>	<b>3,643</b>	<b>236,621</b>	<b>241,614</b>
<b>Expenditures for the year</b>	<b>2,384,033</b>	<b>737,562</b>	<b>3,643</b>	<b>3,125,238</b>	<b>2,760,931</b>
<b>Excess of revenues over expenditures for the year from operations</b>	<b>\$ (38,475)</b>	<b>\$ (115,741)</b>	<b>\$ (26,029)</b>	<b>\$ (180,245)</b>	<b>\$ 891,405</b>
<b>Government assistance</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>10,000</b>
<b>Excess of revenues over expenditures for the year</b>	<b>\$ (38,475)</b>	<b>\$ (115,741)</b>	<b>\$ (26,029)</b>	<b>\$ (180,245)</b>	<b>\$ 901,405</b>
<b>Net Assets, Beginning of Year</b>	<b>\$ 2,119,880</b>	<b>\$ 1,760,958</b>	<b>\$ 401,701</b>	<b>\$ 4,282,539</b>	<b>\$ 3,381,134</b>
<b>Interfund transfer (note 14)</b>	<b>3,321</b>	<b>11,179</b>	<b>(14,500)</b>	<b>-</b>	<b>-</b>
<b>Net Assets, End of Year</b>	<b>\$ 2,084,726</b>	<b>\$ 1,656,396</b>	<b>\$ 361,172</b>	<b>\$ 4,102,294</b>	<b>\$ 4,282,539</b>

The accompanying notes are an integral part of these financial statements

# Brain Tumour Foundation of Canada

## Statement of Financial Position

As at December 31, 2022

	Unrestricted Fund	Restricted Fund	Endowment Fund	Total 2022	Total 2021
<b>Assets</b>					
<b>Current</b>					
Cash	\$ 361,468	\$ 925,223	\$ -	\$ 1,286,691	\$ 1,183,911
Short-term investments (note 3)	24,564	100,000	-	124,564	129,301
Accounts receivable	37,355	-	-	37,355	43,300
Prepaid expenses	77,239	-	-	77,239	84,854
	<b>500,626</b>	<b>1,025,223</b>	<b>-</b>	<b>1,525,849</b>	<b>1,441,366</b>
<b>Long-term investments (note 4)</b>	<b>1,623,496</b>	<b>631,173</b>	<b>-</b>	<b>2,254,669</b>	<b>2,458,585</b>
<b>Property, plant and equipment (note 5)</b>	<b>43,878</b>	<b>-</b>	<b>-</b>	<b>43,878</b>	<b>54,114</b>
<b>Intangible assets (note 6)</b>	<b>30,248</b>	<b>-</b>	<b>-</b>	<b>30,248</b>	<b>49,789</b>
<b>Endowment fund (note 7)</b>	<b>-</b>	<b>-</b>	<b>361,172</b>	<b>361,172</b>	<b>401,701</b>
	<b>\$ 2,198,248</b>	<b>\$ 1,656,396</b>	<b>\$ 361,172</b>	<b>\$ 4,215,816</b>	<b>\$ 4,405,555</b>
<b>Liabilities</b>					
<b>Current</b>					
Accounts payable and accrued liabilities	\$ 73,522	\$ -	\$ -	\$ 73,522	\$ 82,579
Current portion of CEBA loan (note 8)	40,000	-	-	40,000	-
Current portion of capital lease obligation	-	-	-	-	437
	<b>113,522</b>	<b>-</b>	<b>-</b>	<b>113,522</b>	<b>83,016</b>
<b>CEBA loan (note 8)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>40,000</b>
	<b>113,522</b>	<b>-</b>	<b>-</b>	<b>113,522</b>	<b>123,016</b>
<b>Commitments (note 9)</b>					
<b>Fund Balances</b>					
<b>Unrestricted Fund</b>	<b>2,084,726</b>	<b>-</b>	<b>-</b>	<b>2,084,726</b>	<b>2,119,880</b>
<b>Restricted Fund (note 11)</b>	<b>-</b>	<b>1,656,396</b>	<b>-</b>	<b>1,656,396</b>	<b>1,760,958</b>
<b>Endowment Fund (note 7)</b>	<b>-</b>	<b>-</b>	<b>361,172</b>	<b>361,172</b>	<b>401,701</b>
	<b>2,084,726</b>	<b>1,656,396</b>	<b>361,172</b>	<b>4,102,294</b>	<b>4,282,539</b>
	<b>\$ 2,198,248</b>	<b>\$ 1,656,396</b>	<b>\$ 361,172</b>	<b>\$ 4,215,816</b>	<b>\$ 4,405,555</b>

On behalf of the Board:

\_\_\_\_\_

\_\_\_\_\_

The accompanying notes are an integral part of these financial statements

**Brain Tumour Foundation of Canada**  
**Statement of Cash Flows**  
Year ended December 31, 2022

	2022	2021
<b>Cash provided by (used for) the following activities</b>		
<b>Operating activities</b>		
Excess of revenues over expenditures for the year	\$ (180,245)	\$ 901,405
Items not affecting cash		
Amortization	50,716	54,605
Unrealized loss (gain) on investments	252,057	(75,118)
Forgiveable portion of CEBA loan	-	(10,000)
	<b>122,528</b>	<b>870,892</b>
Changes in non-cash working capital balances		
Decrease (increase) in accounts receivable	5,945	(21,457)
Decrease in prepaid expenses	7,615	9,562
Increase (decrease) in accounts payable and accrued liabilities	(9,057)	55,416
Decrease in grants payable	-	(250,000)
	<b>127,031</b>	<b>664,413</b>
<b>Investing activities</b>		
Decrease (increase) in investments	(43,404)	(694,929)
Purchase of property, plant, and equipment	(20,939)	(9,306)
Purchase of intangible assets	-	(42,293)
Decrease (increase) in Endowment Fund investments	40,529	(31,312)
	<b>(23,814)</b>	<b>(777,840)</b>
<b>Financing activities</b>		
Repayment of capital lease obligation	(437)	(16,849)
Proceeds of CEBA loan	-	20,000
	<b>(437)</b>	<b>3,151</b>
<b>Change in cash position</b>	<b>102,780</b>	<b>(110,276)</b>
<b>Cash, beginning of year</b>	<b>1,183,911</b>	<b>1,294,187</b>
<b>Cash, end of year</b>	<b>\$ 1,286,691</b>	<b>\$ 1,183,911</b>
<b>Cash resources are comprised of:</b>		
Cash - unrestricted fund	\$ 361,468	\$ 351,380
Cash - restricted fund	925,223	832,531
	<b>\$ 1,286,691</b>	<b>\$ 1,183,911</b>

*The accompanying notes are an integral part of these financial statements*

**Brain Tumour Foundation of Canada**  
**Notes to the Financial Statements**  
*For the year ended December 31, 2022*

---

**1. Nature of operations**

The Brain Tumour Organization of Canada (the "Organization") was incorporated on February 11, 1985 as a registered charity and is a national organization dedicated to reaching every person in Canada affected by a brain tumour through support, education, information and research.

**2. Significant accounting policies**

These financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations. These financial statements have, in management's opinion, been properly prepared within the framework of the accounting policies summarized as follows.

**(a) Fund accounting**

The Organization has the following funds:

**(i) Unrestricted Fund**

The Unrestricted Fund accounts for the day to day operating activities of the Organization, including any unrestricted fundraising events revenue, donations, other revenue and net investment income.

**(ii) Restricted Fund**

The Restricted Fund consists of externally restricted fundraising events revenue and donations that are to be used in accordance with restrictions in place and require Board of Directors approval for payment.

**(iii) Endowment Fund**

The Endowment Fund is held by the London Community Organization and consists of six funds: Hannah Patterson Legacy Fund, Kelly Northey Legacy Fund, David Bloom Legacy Fund, R. Angus King Legacy Fund, Pam and Rolando Del Maestro Family and the Brain Tumour Organization (General) Fund.

**(b) Revenue recognition**

The Organization follows the restricted fund method of accounting for contributions.

Restricted contributions including fundraising events, donations and other revenue are recognized as revenue of the restricted fund in the period in which they are received or receivable.

Unrestricted contributions including fundraising events, donations and other revenue are recognized as revenue of the unrestricted fund in the period in which they are received or receivable.

Restricted net investment income is recognized as revenue of the restricted fund in the year in which it is received or receivable. Unrestricted net investment income is recognized as revenue of the unrestricted fund when it is received or receivable. Investment gains and losses are recognized as revenue whether realized or unrealized.

Endowment contributions are recognized as revenue of the endowment fund in the period in which they are received or receivable. Net investment income is added to the principal amount of resources held for endowment in the statement of operations.

**(c) Recognition of pledges**

Because of the uncertainty of the collectability of pledges, the Organization recognizes only those pledges for which contributions have been received at the date of completion of these financial statements.



# Brain Tumour Foundation of Canada

## Notes to the Financial Statements

For the year ended December 31, 2022

---

### 2. Significant accounting policies (continued from previous page)

#### (d) Property, plant and equipment

Property, plant and equipment are recorded at cost. The Organization provides for amortization using the following methods at rates designed to amortize the cost of the property, plant and equipment over their estimated useful lives. The annual amortization rates and methods are as follows:

Office equipment	5 years	Straight-line
Leasehold improvements	10 years	Straight-line
Computer equipment	3 years	Straight-line
Signs	5 years	Straight-line
Asset under capital lease	5 years	Straight-line

#### (e) Intangible assets

Logos represent the cost of English and French registered logos designed for the Organization in 2002. Logos are recorded at cost and amortized over their estimated useful lives of 10 years. Website is recorded at cost and amortized over the estimated useful life of 3 years. Computer software is recorded at cost and amortized over the estimated useful life of 5 years.

These intangible assets are tested for impairment only when an event or circumstance occurs indicating that the fair value may be lower than their carrying amount.

#### (f) Grants payable

Grants are recorded upon approval of the Committees of the Board of Directors. If ethics approval is required, this is obtained from the institution in which the project is conducted prior to any funds being disbursed. If the project does not involve human and/or animal subjects, ethics approval is not required. The funds are paid to the recipient according to the payment terms specified in the grant agreement.

#### (g) Volunteer contributions

Volunteers contribute countless hours to assist the Organization in carrying out its fundraising activities. Due to the difficulty in determining fair value, volunteer contributions are not recognized in the financial statements.

#### (h) Income taxes

According to the provisions of the Income Tax Act (Canada), the Organization is exempt from taxes on income.

During the year, the Organization expended sufficient amounts on charitable activities and by way of gifts to qualified donees to meet the disbursement quota requirements as defined in paragraph 149(1)(f) of the Income Tax Act (Canada).

**2. Significant accounting policies (continued from previous page)**

**(i) Financial instruments**

**(i) Measurement of financial instruments**

The Organization initially measures its financial assets and financial liabilities at fair value adjusted by, in the case of a financial instrument that will not be measured subsequently at fair value, the amount of transaction costs directly attributable to the instrument.

Related party financial instruments are measured at cost on initial recognition. When the financial instrument has repayment terms, cost is determined using the undiscounted cash flows, excluding interest, dividend, variable and contingent payments, less any impairment losses previously recognized by the transferor. When the financial instrument does not have repayment terms, but the consideration transferred has repayment terms, cost is determined based on the repayment terms of the consideration transferred. When the financial instrument and the consideration transferred both do not have repayment terms, the cost is equal to the carrying or exchange amount of the consideration transferred or received.

The Organization subsequently measures its financial assets and financial liabilities at amortized cost, except for bonds, common shares and other marketable securities quoted in an active market, which are subsequently measured at fair value. Changes in fair value are recognized in net income.

Financial assets measured at amortized cost include cash and accounts receivable. Financial assets measured at fair value include short-term investments, Endowment fund and long-term investments.

Financial liabilities measured at amortized cost include accounts payable and accrued liabilities, CEBA loan and grants payable.

**(ii) Impairment**

Financial assets measured at amortized cost are tested for impairment when there are indicators of possible impairment. When a significant adverse change has occurred during the period in the expected timing or amount of future cash flows from the financial asset or group of assets, a write-down is recognized in net income. The write down reflects the difference between the carrying amount and the higher of:

- ♦ the present value of the cash flows expected to be generated by the asset or group of assets;
- ♦ the amount that could be realized by selling the assets or group of assets;
- ♦ the net realizable value of any collateral held to secure repayment of the assets or group of assets.

When the events occurring after the impairment confirm that a reversal is necessary, the reversal is recognized in net income up to the amount of the previously recognized impairment.

**(j) Expense allocations**

The Organization allocates its general expenses, with the exception of marketing and communications, between administrative, other fundraising and patient services based on percentages. This allocation basis consists of 7% to administrative, 18% to other fundraising and 75% to patient services. Marketing and communications expenses are allocated 15% to other fundraising and 85% to patient services. The Organization believes that these allocation rates are appropriate and evaluates the rates annually.

**(k) Use of estimates**

The preparation of financial statements in conformity with Canadian accounting standards for not-for-profit organizations requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. By their nature, these estimates are subject to measurement uncertainty. These estimates are reviewed periodically, and adjustments are made to income in the year in which they become known. Accounts specifically affected by estimates in these financial statements are the useful life of property, plant and equipment, useful life of intangible assets, and in-kind donations. Actual results may vary from these estimates.

# Brain Tumour Foundation of Canada

## Notes to the Financial Statements

For the year ended December 31, 2022

### 2. Significant accounting policies (continued from previous page)

#### (l) In kind donations

Materials and services donated to the Organization that are normally purchased, are recorded at their fair value as a donation and corresponding expense. In 2022 in kind donations amounted to \$3,694 (2021 - \$NIL).

#### (m) Government assistance

Government assistance is recognized when there is reasonable assurance that the entity has met the eligibility criteria and the grant will be received.

### 3. Short term investments

Short term investments, which include fixed income and equity securities, are recorded at fair market value and consist of:

	<u>2022</u>	<u>2021</u>
RBC portfolio	<b>\$ 124,564</b>	\$ 129,301

Included in the short term investments are restricted investments of \$100,000 (2021 - \$100,000) held in Research Fellowship Funds.

### 4. Long term investments

Long-term investments, which include fixed income and equity securities, are recorded at fair market value and consist of:

	<u>2022</u>	<u>2021</u>
RBC portfolio	<b>\$ 2,254,669</b>	\$2,458,585

The long term investments consist of two portfolios: an internally designated stability fund and the restricted research fund investments.

The Organization's Board of Directors considers the investments in the stability account to be allocated for the ensured continuance of the Organization, and the earnings from those funds will be used to fulfil the priorities identified in the Organization's mission statement.

The research funds are invested and held as the William Donald Nash Research Fellowship Fund, Richard Motyka Research Fellowship Fund, A.E. Research Fund and the Dunn with Cancer Research Fund. The goal of these funds is to support clinical and/or basic science research through research grant payments approved by the board.

# Brain Tumour Foundation of Canada

## Notes to the Financial Statements

*For the year ended December 31, 2022*

### 5. Property, plant and equipment

	<b>2022</b>	<b>2021</b>	
	<i>Cost</i>	<i>Accumulated amortization</i>	<i>Net</i>
Office equipment	\$ 192,660	\$176,957	\$15,703
Leasehold improvements	10,687	5,877	4,810
Computer equipment	187,467	164,102	23,365
Signs	8,551	8,551	-
	<b>399,265</b>	<b>355,487</b>	<b>-</b>
Asset under capital lease	-	-	-
	<b>\$ 399,365</b>	<b>\$355,487</b>	<b>\$43,878</b>
			\$ 30,892
			5,878
			13,689
			855
			51,314
			2,800
			\$ 54,114

The amortization for 2022 was \$31,175 (2021 - \$36,438).

### 6. Intangible assets

	<b>2022</b>	<b>2021</b>	
	<i>Cost</i>	<i>Accumulated amortization</i>	<i>Net</i>
Registered logos	\$ 26,482	\$ 25,883	\$ 599
Website	185,587	155,937	29,650
Computer software	161,664	161,664	-
	<b>\$ 373,733</b>	<b>\$ 343,485</b>	<b>\$ 30,248</b>
			\$ 684
			49,105
			-
			\$ 49,789

The amortization of intangible assets for 2022 was \$19,541 (2021 - \$18,167).

### 7. Endowment Fund

The Organization has established an Endowment Fund with the London Community Organization. Each year the investment income from this fund is to be used to benefit the work of the Organization. The Endowment Fund is recorded at fair value. The balance consists of the following funds:

	<b>2022</b>	<b>2021</b>
General	\$ 24,057	\$ 26,882
Kelly Northey Legacy	31,177	33,618
David Bloom Legacy	35,867	39,444
Hannah Patterson Legacy	77,477	86,567
R. Angus King Legacy	134,767	150,578
Pam and Rolando Del Maestro Family	57,827	64,612
	<b>\$361,172</b>	<b>\$ 401,701</b>

**Brain Tumour Foundation of Canada**  
**Notes to the Financial Statements**  
*For the year ended December 31, 2022*

---

**8. CEBA loan**

In the previous year, the Organization was approved for and received a \$40,000 loan payable ("CEBA loan") with the Royal Bank of Canada under the Canada Emergency Business Account ("CEBA") program funded by the Government of Canada. During the current year, the Organization has qualified for the additional \$20,000 extension of the CEBA loan. The CEBA loan is non-interest bearing, can be repaid at any time without penalty and is valid until December 31, 2023.

If \$40,000 of the CEBA loan is repaid on or before December 31, 2023, the repayment of the remaining \$20,000 shall be forgiven. If on December 31, 2023, the Organization exercises the option for a 2 -year term extension, 5% interest during the term extension period will apply on any balance remaining.

**9. Commitments**

The Organization leases office space and equipment under operating lease agreements. The London office space leases on Horton Street expire January 2024. The aggregate minimum lease payments including HST are as follows:

2023	173,966
2024	70,019
2025	10,129
2026	10,129
<hr/>	
Total future minimum lease payments	\$264,243

*Blackbaud agreement*

The Organization has made an annual commitment of \$54,875 for 2023 to obtain subscription-based computer software. The Organization paid \$32,896 in 2022 per the agreement with Blackbaud.

**Future Grant Commitments**

*Brain Tumour Tissue Bank Project*

The Organization has committed to a donation of \$6,574 in 2023 for the Tissue Bank Project administered by the London Health Sciences Centre.

*William Donald Nash Fellowship Award*

In 2020 the Organization has approved the contribution of \$100,000 towards this fellowship; \$25,000 is to be paid annually over 2020 to 2023. During the year \$25,000 (2021 - \$25,000) was expensed. The remaining \$25,000 has not been accrued in the financial statements as there are future conditions that need to be met prior to their eligibility for release.

*Studentship awards*

The Organization has approved the contribution of \$20,000 towards research grants; the first \$10,000 was paid to two recipients equally in 2022 and the second installment is to be paid in 2023. During the year, \$10,000 was expensed, the remaining \$10,000 has not been accrued in the financial statements as there are future conditions that need to be met prior to their eligibility for release.

# Brain Tumour Foundation of Canada

## Notes to the Financial Statements

*For the year ended December 31, 2022*

### 10. Commitments (continued)

#### *Brain Registry*

The Organization has approved the grants to the recipient's research in 2021. Funds of \$60,256 was expensed in 2022, \$34,000 to be paid in 2023, and the remaining \$70,256 to be paid out in 2024. These funds have not been accrued in the financial statements as there are future conditions that need to be met prior to their eligibility for release.

#### *Dunn with Cancer Brain Tumor Research Fellowship*

The Organization has approved the award to the recipient with a two-year Fellowship for research which will be conducted between September 13, 2022 and September 13, 2024. This is a \$100,000 award, payable over two years in two equal installments of \$50,000. The first payment was released in 2022, the second payment has not been accrued in the financial statements as there are future conditions that need to be met prior to its eligibility for release.

#### *Defeating Embryonal Cancer in Young People Together (DECRYPT)*

The Organization has approved the award to the recipient with a 4 year grant designed to fund research which will be conducted between 2023 and 2026. This is a \$50,000 award, payable over four years in equal installments of \$12,500. Payments will start in 2023 and have not been accrued in the financial statements as there are future conditions that need to be met prior to its eligibility for release.

### 11. Restricted Fund

The Organization's restricted fund consists of the following balances at year-end:

	<b>2022</b>	<b>2021</b>
A.E. Research Fund	<b>\$277,753</b>	\$ 402,753
Brainwave	<b>35,286</b>	27,406
Programs & Services	<b>57,343</b>	44,343
Research – General	<b>256,910</b>	257,728
Research – Pediatric	<b>187,834</b>	154,692
Research – Registry	<b>169,783</b>	223,698
Research – Studentship	<b>21,065</b>	36,050
Richard Motyka Research Fellowship Fund	<b>4,657</b>	54,657
William Donald Nash Research Fellowship Fund	<b>150,106</b>	175,106
Dunn with Cancer Research Fund	<b>298,656</b>	296,068
Vikes Kick Cancer Fund	<b>125,174</b>	71,291
Youth Education Awards	<b>22,916</b>	17,166
Trevor Harrison Student Bursary Fund	<b>48,913</b>	-
	<b>\$1,656,396</b>	\$ 1,760,958

### 12. Other revenue

Other revenue consists of Nevada, registration fees, interest income on bank accounts and tissue bank payments.

**Brain Tumour Foundation of Canada**  
**Notes to the Financial Statements**

*For the year ended December 31, 2022*

**13. Investment income**

Investment income and losses are broken down between realized and unrealized amounts as follows:

	<i>2022</i>	
	<i>Unrestricted</i>	<i>Endowment</i>
Other	\$5,195	\$(23,815)
Interest	31,963	-
Dividends	12,555	-
Capital loss	(2,075)	-
Unrealized loss	(252,057)	-
	\$(204,419)	\$(23,815)

	<i>2021</i>	
	<i>Unrestricted</i>	<i>Endowment</i>
Other	\$ 46,448	\$ 46,018
Interest	23,683	-
Dividends	9,008	-
Capital loss	(6,649)	-
Unrealized gain	75,118	-
	\$ 147,608	\$ 46,018

**14. Interfund transfers**

During the year, the board approved the transfer of \$11,179 (2021 - \$10,022) from the Endowment Fund to the Restricted Fund to be spent in accordance with donor instructions. The board also approved the transfer of \$3,321 (2021 - \$2,978) from the Endowment Fund to the Unrestricted Fund.

**15. Comparative figures**

The prior year figures have been reclassified, where applicable, to conform to the presentation used in the current year. The changes do not affect prior year excess of revenues over expenditures or net assets.

**16. Financial instruments and risks**

The Organization has policies and procedures to establish a target asset mix to help protect against the follow risks:

*Interest rate risk*

The Organization is exposed to interest rate risk as the value of the assets is affected by market changes in interest rates. Interest rate changes directly impact the value of the fixed income securities.

*Market risk*

The value of equity securities changes with stock market conditions, which are affected by general economic and market conditions. The value of securities will vary with developments within the specific companies or governments which issues the securities. The Organization manages this risk through controls to monitor and limit concentration levels.

*Liquidity risk*

Liquidity risk is the risk that the Organization will not be able to meet its obligations as they become due. The Organization manages this risk by establishing budgets and funding plans. Cash is held in an interest bearing account which provides a rate of return as well as liquidity.

*Credit risk*

The financial instruments that potentially subject the Organization to a significant concentration of credit risk consist primarily of cash, short-term investments, long-term investments and Endowment Fund. The Organization mitigates its exposure to credit loss by placing its cash and investments with a Chartered Canadian Bank.

There have been no changes in the Organization's risk exposures from the prior year.